Pacer Advisors Inc. Grows Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Pacer Advisors Inc. raised its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 40.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 1,820,913 shares of the specialty pharmaceutical company’s stock after purchasing an additional 527,187 shares during the period. Pacer Advisors Inc. owned 2.89% of Jazz Pharmaceuticals worth $194,346,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. AE Wealth Management LLC bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at approximately $270,000. Intech Investment Management LLC bought a new position in shares of Jazz Pharmaceuticals in the second quarter worth approximately $1,336,000. XTX Topco Ltd purchased a new stake in shares of Jazz Pharmaceuticals in the second quarter worth $788,000. Seven Eight Capital LP bought a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter valued at $686,000. Finally, Hsbc Holdings PLC raised its position in shares of Jazz Pharmaceuticals by 49.6% during the 2nd quarter. Hsbc Holdings PLC now owns 45,344 shares of the specialty pharmaceutical company’s stock valued at $4,894,000 after purchasing an additional 15,041 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 0.5 %

Shares of NASDAQ:JAZZ opened at $110.76 on Friday. The company has a market cap of $6.98 billion, a price-to-earnings ratio of 22.84, a PEG ratio of 1.31 and a beta of 0.57. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $137.38. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. The company has a 50-day moving average price of $110.79 and a 200 day moving average price of $111.09.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.80 by $0.87. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1 billion. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. As a group, equities research analysts predict that Jazz Pharmaceuticals plc will post 16.03 earnings per share for the current year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 4.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on JAZZ. Piper Sandler cut their price target on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a research note on Thursday, August 1st. The Goldman Sachs Group initiated coverage on Jazz Pharmaceuticals in a research report on Wednesday, June 5th. They set a “buy” rating and a $169.00 target price for the company. Morgan Stanley lowered their price target on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a report on Friday, July 12th. Cantor Fitzgerald restated an “overweight” rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Finally, UBS Group reduced their price objective on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a research report on Tuesday, July 2nd. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $173.07.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.